Compare Ishares Msci Italy ETF (EWI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Johnson & Johnson — how do they compare? Ishares Msci Italy ETF trades at $56.08 (market cap $1.14B), while Johnson & Johnson trades at $260.76 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 542.2× Ishares Msci Italy ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Johnson & Johnson for 129 Days on average.
| EWI | JNJ | |
|---|---|---|
Market Cap | $1.14B | $618.09B |
Volume | 2,377,947 | 6,050,983 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $278.43 |
52-Week Low | $50.31 | $186.00 |
Typical Hold Time | 52 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
